AIチャット

Twist Bioscience Corporation

TWST · NasdaqGS · USD

139.77 +7.02 (5.29%)

Oct 19, 2026, 4:00 PM EDT - 取引時間中

出来高
1.59M

Twist Bioscience Corporation(TWST)の株価・分析・データ

間隔:1D
ローソク足とシグナルを読み込み中…

本源的価値

バリュエーションモデルは Pro の機能です。サインインまたはアップグレードすると分析全体を表示できます。

プランを見る →

アナリスト予想

株価予想 →

目標株価

$45.00 – $215.00

中央値 $188.50 · 34.86% 上昇余地

12か月目標株価 · アナリスト12人

アナリストのコンセンサス: 買い

無料の概要を表示しています

無料アカウントを作成して、この銘柄に関するさらに詳しいリサーチをご覧ください。

業績

財務情報を見る →

読み込み中...

最新決算

実績予想との差前年比
売上高$118.4Mn/a+23.24%
EPS(TTM)-$0.56-$0.28-19.15%

次回決算

寄り付き前の予定です。

予想 · アップグレード →

決算の詳細を見る →

事業指標

買気配
100.4
純利益(TTM)
-137M
2.19
-2.23
n/a
-349.43
PBR(TTM)
19.65
PSR(TTM)
21.46
決算発表日
Nov 16, 2026
売気配
173.29
出来高
1,591,262
平均出来高(20日)
2,172,248
始値
136.99
前日終値
132.75
当日レンジ
133.72 - 141.80
52週レンジ
23.30 - 219.71
目標株価
188.5 (34.86%)
配当
n/a
権利落ち日
n/a

Twist Bioscience Corporationについて

企業情報を見る →
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Biotechnology · Healthcare

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

セクター Healthcare
IPO日 Oct 31, 2018
従業員数 979
上場取引所 NasdaqGS
ティッカー TWST